JMP Securities Raises ACAD Target to $27 PT.. ) The Fly On The Wall Link )
The Fly On The Wall
June 14, 2013
08:27 EDT ACAD ACADIA price target raised to $27 from $16 at JMP Securities
JMP Securities increased its price target on ACADIA to reflect the broader potential for the company's pimavanserin in indications beyond Parkinson’s disease psychosis, including Alzheimer’s diseasepsychosis and schizophrenia. The firm reiterates an Outperform rating on the stock.
From here it is 40%+ gain. I look forward to this and the upcoming upgrades. The need for this medication is immense and the revenue will be of magnitude. The Baker Bros are probably eyeing at the very least a triple from this level... their recent buys a few weeks ago at 12-14 are already a double once we reach the target set by JMP Securities.